CYP2C9 and neoplasm: The quantified IHC data showed that the TNBC specimens may be classified as strongly positive against CYP2J2 (58%) and strong positive/positive against CYP2C9/19 (57% strong positive and 33% positive) antibodies, respectively, which are in good agreement with the high level of EETs and CYP expoxygenase/sEH gene overexpression detected in the same tumor specimen.